Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)
Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –
Protalix BioTherapeutics total assets
Total assets on the balance sheet at the end of each period.
Protalix BioTherapeutics's total assets was $118.24M at Sep 30, 2026. For fiscal 2025 it was $82.35M, up 12.2% from the year before. Over ten years it grew -1.7% a year on average. The highest annual figure on record is $113.33M in fiscal 2013.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.35M | +12.2% |
| FY2024 | Dec 31, 2024 | $73.42M | -13.0% |
| FY2023 | Dec 31, 2023 | $84.43M | +51.4% |
| FY2022 | Dec 31, 2022 | $55.79M | -24.3% |
| FY2021 | Dec 31, 2021 | $73.67M | +8.4% |
| FY2020 | Dec 31, 2020 | $67.93M | +49.7% |
| FY2019 | Dec 31, 2019 | $45.39M | -25.7% |
| FY2018 | Dec 31, 2018 | $61.13M | -15.3% |
| FY2017 | Dec 31, 2017 | $72.21M | -12.2% |
| FY2016 | Dec 31, 2016 | $82.25M | -15.4% |
| FY2015 | Dec 31, 2015 | $97.25M | +24.1% |
| FY2014 | Dec 31, 2014 | $78.36M | -30.9% |
| FY2013 | Dec 31, 2013 | $113.33M | +44.0% |
| FY2012 | Dec 31, 2012 | $78.73M | +52.0% |
| FY2011 | Dec 31, 2011 | $51.81M | -20.0% |
| FY2010 | Dec 31, 2010 | $64.73M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $118.24M | +43.7% |
| Q2 FY2026 | Jun 30, 2026 | $110.34M | +40.6% |
| Q1 FY2026 | Mar 31, 2026 | $102.34M | +38.5% |
| Q4 FY2025 | Dec 31, 2025 | $82.35M | +12.2% |
| Q3 FY2025 | Sep 30, 2025 | $82.26M | +33.6% |
| Q2 FY2025 | Jun 30, 2025 | $78.49M | -14.3% |
| Q1 FY2025 | Mar 31, 2025 | $73.89M | -17.7% |
| Q4 FY2024 | Dec 31, 2024 | $73.42M | -13.0% |
| Q3 FY2024 | Sep 30, 2024 | $61.56M | -29.7% |
| Q2 FY2024 | Jun 30, 2024 | $91.54M | +3.5% |
| Q1 FY2024 | Mar 31, 2024 | $89.83M | +35.0% |
| Q4 FY2023 | Dec 31, 2023 | $84.43M | +51.4% |
| Q3 FY2023 | Sep 30, 2023 | $87.57M | +54.4% |
| Q2 FY2023 | Jun 30, 2023 | $88.42M | +45.8% |
| Q1 FY2023 | Mar 31, 2023 | $66.56M | -2.7% |
| Q4 FY2022 | Dec 31, 2022 | $55.79M | -24.3% |
| Q3 FY2022 | Sep 30, 2022 | $56.71M | -32.1% |
| Q2 FY2022 | Jun 30, 2022 | $60.64M | -44.0% |
| Q1 FY2022 | Mar 31, 2022 | $68.39M | -33.5% |
| Q4 FY2021 | Dec 31, 2021 | $73.67M | +8.4% |
| Q3 FY2021 | Sep 30, 2021 | $83.48M | +15.5% |
| Q2 FY2021 | Jun 30, 2021 | $108.20M | +30.6% |
| Q1 FY2021 | Mar 31, 2021 | $102.79M | +126.5% |
| Q4 FY2020 | Dec 31, 2020 | $67.93M | +26.4% |
| Q3 FY2020 | Sep 30, 2020 | $72.31M | +30.9% |
| Q1 FY2020 | Mar 31, 2020 | $82.88M | +35.8% |
| Q4 FY2019 | Dec 31, 2019 | $45.39M | -25.7% |
| Q3 FY2019 | Sep 30, 2019 | $53.73M | -18.3% |
| Q2 FY2019 | Jun 30, 2019 | $55.24M | +6.8% |
| Q1 FY2019 | Mar 31, 2019 | $61.04M | -5.8% |
| Q4 FY2018 | Dec 31, 2018 | $61.13M | -15.3% |
| Q3 FY2018 | Sep 30, 2018 | $65.75M | +7.7% |
| Q2 FY2018 | Jun 30, 2018 | $51.72M | -12.3% |
| Q1 FY2018 | Mar 31, 2018 | $64.80M | -9.8% |
| Q4 FY2017 | Dec 31, 2017 | $72.21M | -12.2% |
| Q3 FY2017 | Sep 30, 2017 | $61.06M | -13.4% |
| Q2 FY2017 | Jun 30, 2017 | $59.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $71.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $82.25M | – |
| Q3 FY2016 | Sep 30, 2016 | $70.47M | – |
See a number that looks wrong?